Identification of Combinations of Plasma lncRNAs and mRNAs as Potential Biomarkers for Precursor Lesions and Early Gastric Cancer

Chen, Lu; Ge, Chang‐Hui; Feng, Xiuxue; Fu, Hanjiang; Wang, Shasha; Zhu, Jing; Linghu, Enqiang; Zheng, Xiaofei

doi:10.1155/2022/1458320

Cited by 7 publications

(3 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, PPBP has also been identified as a biomarker for other diseases, such as cancers ( e.g . gastric cancer ( Chen et al, 2022 ) and thyroid carcinoma ( Zhang et al, 2021b )), inflammation ( e.g . rheumatoid arthritis ( Guerrero et al, 2021 )), neurosyphilis ( Li et al, 2020 ), COVID-19 ( Yatim et al, 2021 ), and metabolic disease ( e.g .…”

Section: Discussionmentioning

confidence: 99%

PPBP gene as a biomarker for coronary heart disease risk in postmenopausal Thai women

Mansanguan

Maneerat

2022

PeerJ

View full text Add to dashboard Cite

Background Estrogen is an important ovarian hormone with anti-atherogenic and cardioprotective effects. Postmenopausal women have lower estrogen levels, associated with significantly higher risks of coronary heart disease (CHD) and CHD-related death. Effective biomarkers for the diagnosis, prediction, and treatment of CHD are needed to address this problem and thus reduce the mortality due to CHD in postmenopausal women. We recently reported that the PPBP and DEFA1/DEFA3 genes may be feasible synergistic biomarkers for CHD risk in Thai men with hyperlipidemia. The PPBP gene encodes pro-platelet basic protein (PPBP) from activated platelets, and DEFA1/DEFA3 encodes human neutrophil peptides (HNP) 1–3, mainly produced by activated neutrophils. Both platelets and neutrophils are involved in chronic inflammation during the development of atherogenesis and CHD. This study investigated the potential roles of PPBP and DEFA1/DEFA3 and their proteins as biomarkers for CHD risk in postmenopausal Thai women. Methods This cross-sectional study enrolled 90 postmenopausal Thai women, including 12 healthy controls (N), 18 patients with hyperlipidemia (H), and 21 patients diagnosed with CHD. The remaining 39 women were receiving cholesterol-lowering drugs for hyperlipidemia (HD) were excluded from the study. All CHD patients underwent coronary bypass grafting or coronary angioplasty. PPBP and DEFA1/DEFA3 mRNA expression levels in peripheral blood mononuclear cells isolated from heparinized blood were determined by quantitative reverse-transcription polymerase chain reaction. Levels of PPBP and HNP-1–3 proteins in corresponding plasma samples were assessed by enzyme-linked immunosorbent assay. Differences in parameters were compared among groups and correlations between parameters and clinical manifestations were analyzed. Results PPBP mRNA and protein levels were significantly increased in the CHD group compared with the N and H groups. In contrast, DEFA1/DEFA3 mRNA and HNP-1–3 protein levels did not differ significantly among the groups. None of the levels were associated with any of the clinical parameters analyzed in this study. Conclusion The results indicate that gene and protein expression levels of PPBP, but not DEFA1/DEFA3, and HNP-1–3, may be feasible biomarkers for assessing CHD risk in postmenopausal Thai women with hyperlipidemia.

show abstract

Section: Discussionmentioning

confidence: 99%

PPBP gene as a biomarker for coronary heart disease risk in postmenopausal Thai women

Mansanguan

Maneerat

2022

PeerJ

View full text Add to dashboard Cite

show abstract

“…Another study showed that CEBPA-DT was upregulated in cisplatin resistance OSCC cells, CEBPA-DT regulated cisplatin chemosensitivity through CEBPA/BCL2-mediated cell apoptosis [ 40 ]. For gastrointestinal cancer, the prognostic value of CEBPA-DT was illustrated along with several other lncRNAs (INHBA-AS1, AK001058, UCA1, PPBP, and RGS18) in early gastric cancer [ 41 ]. Last but foremost, a recently published paper documented that CEBPA-DT was capable of promoting the EMT process and liver cancer progression [ 32 ], but the mechanism underlying the promoting effect was not illuminated.…”

Section: Discussionmentioning

confidence: 99%

LncRNA CEBPA-DT promotes liver cancer metastasis through DDR2/β-catenin activation via interacting with hnRNPC

Cai

Lyu

et al. 2022

J Exp Clin Cancer Res

View full text Add to dashboard Cite

Background Hepatocellular carcinoma (HCC) is the world’s third leading cause of cancer-related death; due to the fast growth and high prevalence of tumor recurrence, the prognosis of HCC patients remains dismal. Long non-coding RNA CEBPA-DT, a divergent transcript of the CCAAT Enhancer Binding Protein Alpha (CEBPA) gene, has been shown to participate in multiple tumor progression. However, no research has established its cancer-promoting mechanism in HCC yet. Methods CEBPA-DT was identified in human HCC tissues through RNA sequencing. The expression level of CEBPA-DT was assessed by quantitative real-time PCR. The biological effects of CEBPA-DT were evaluated in vitro and in vivo through gain or loss of function experiments. RNA fluorescence in situ hybridization (FISH), RNA immunoprecipitation (RIP) and RNA pull-down assays were applied to investigate the downstream target of CEBPA-DT. Immunofluorescence, subcellular protein fractionation, western blot, and co-immunoprecipitation were performed to analyze the subcellular location of β-catenin and its interaction with Discoidin domain-containing receptor 2 (DDR2). Results CEBPA-DT was upregulated in human HCC tissues with postoperative distant metastasis and intimately related to the worse prognosis of HCC patients. Silencing of CEBPA-DT inhibited the growth, migration and invasion of hepatoma cells in vitro and in vivo, while enhancement of CEBPA-DT played a contrasting role. Mechanistic investigations demonstrated that CEBPA-DT could bind to heterogeneous nuclear ribonucleoprotein C (hnRNPC), which facilitated cytoplasmic translocation of hnRNPC, enhanced the interaction between hnRNPC and DDR2 mRNA, subsequently promoted the expression of DDR2. Meanwhile, CEBPA-DT induced epithelial-mesenchymal transition (EMT) process through upregulation of Snail1 via facilitating nuclear translocation of β-catenin. Using DDR2 inhibitor, we revealed that the CEBPA-DT induced the interaction between DDR2 and β-catenin, thus promoting the nuclear translocation of β-catenin to activate transcription of Snail1, contributing to EMT and HCC metastasis. Conclusions Our results suggested that CEBPA-DT promoted HCC metastasis through DDR2/β-catenin mediated activation of Snail1 via interaction with hnRNPC, indicating that the CEBPA-DT-hnRNPC-DDR2/β-catenin axis may be used as a potential therapeutic target for HCC treatment.

show abstract

“…This model serves as a more precise diagnostic biomarker than CA19-9 and CEA. Chen et al conducted a study on a combination of four lncRNAs (CEBPA-AS1, INHBA-AS1, AK001058, and UCA1) and two miRNAs (PPBP and RGS18) 177 . They discovered that the combination of three lncRNAs (INHBA-AS1, AK001058, and UCA1) and one miRNA (RGS18) had the best diagnostic performance, with an AUC of 0.820, sensitivity of 0.782, and specificity of 0.708 177 .…”

Section: Biomarker Screening For Early Gastric Cancermentioning

confidence: 99%

Global progress and future prospects of early gastric cancer screening

Huang,

Shao,

et al. 2024

J. Cancer

View full text Add to dashboard Cite

Gastric cancer is a prevalent malignancy that poses a serious threat to global health. Despite advances in medical technologies, screening methods, and public awareness, gastric cancer remains a significant cause of morbidity and mortality worldwide. Early gastric cancer frequently does not present with characteristic symptoms, while advanced stage disease is characterized by a dismal prognosis. As such, early screening in gastric cancer is of great importance. In recent years, advances have been made globally in both clinical and basic research for the screening of early gastric cancer. The current predominant screening methods for early gastric cancer include imaging screening, endoscopic screening and serum biomarker screening. Imaging screening encompasses upper gastrointestinal barium meal, multidimensional spiral computed tomography (MDCT), Magnetic resonance imaging (MRI), and ultrasonography. Endoscopic screening methods include white light endoscopy, chromoendoscopy, computed virtual chromoendoscopy, and other endoscopic techniques like endocytoscopy, confocal laser endomicroscopy, optical coherence tomography and so on. Biomarkers screening involves the assessment of conventional biomarkers such as CEA, CA19-9 and CA72-4 as well as more emerging biomarkers such as peptides (PG, G-17, GCAA, TAAs and others), DNA (cfDNA, DNA methylation, MSI), noncoding RNA (miRNA, lncRNA, circRNA, and tsRNA) and others. Each screening method has its strengths and limitations. This article systematically summarizes worldwide progress and future development of early gastric cancer screening methods to provide new perspectives and approaches for early diagnostic and treatment advancements in gastric cancer worldwide.

show abstract

Identification of Combinations of Plasma lncRNAs and mRNAs as Potential Biomarkers for Precursor Lesions and Early Gastric Cancer

Cited by 7 publications

References 39 publications

PPBP gene as a biomarker for coronary heart disease risk in postmenopausal Thai women

PPBP gene as a biomarker for coronary heart disease risk in postmenopausal Thai women

LncRNA CEBPA-DT promotes liver cancer metastasis through DDR2/β-catenin activation via interacting with hnRNPC

Global progress and future prospects of early gastric cancer screening

Contact Info

Product

Resources

About